Quantum BioPharma Hires FinnCom for Investor Awareness Campaign
Event summary
- Quantum BioPharma retained FinnCom for a six-month investor awareness campaign starting June 24, 2026.
- The contract includes USD 170,500 in total cash consideration: USD 20,500 upfront and USD 25,000 monthly.
- FinnCom will handle corporate branding, social media, and advertising initiatives for Quantum BioPharma.
- Quantum BioPharma retains a 19.84% stake in Unbuzzd Wellness Inc., with royalty payments of 7% until USD 250 million is reached.
The big picture
Quantum BioPharma’s hiring of FinnCom signals a strategic push to enhance investor relations amid its portfolio expansion in neurodegenerative, metabolic disorders, and alcohol misuse treatments. The company’s focus on both innovative drug development (Lucid-MS) and commercial partnerships (Unbuzzd Wellness Inc.) highlights a dual-track approach to growth. The USD 170,500 investment in marketing underscores the importance of shareholder engagement as Quantum BioPharma navigates competitive biotech landscapes.
What we're watching
- Campaign Effectiveness
- How FinnCom’s investor awareness campaign will impact Quantum BioPharma’s market visibility and shareholder engagement.
- Royalty Milestones
- Whether Unbuzzd Wellness Inc. can achieve the USD 250 million sales target to trigger reduced royalty payments for Quantum BioPharma.
- Lead Compound Progress
- The pace at which Lucid-MS advances through preclinical and clinical development stages.